REACT: A Novel Scoring Model for Predicting Recurrence Risk in Rectal Cancer Following Neoadjuvant Therapy and Curative Intent Surgery

Imagine the human body as a bustling, high-tech city. Inside this city, a rogue gang of cells has decided to take over a specific district: the rectum. This is rectal cancer. For a long time, doctors have tried to predict how this gang will behave after they've been kicked out of the city center (surgery) and the surrounding area has been cleaned up with a chemical spray (chemotherapy and radiation). They've used old maps called "TNM staging," which basically count how deep the gang dug their tunnels and how many lookouts they had. But here's the problem: two gangs can look identical on the map, yet one might hide quietly while the other explodes back into action a year later. The old maps just can't see the invisible forces at play.

Scientists have recently realized that the city's own defense force—the immune system—leaves behind clues about how aggressive the gang really is. Think of it like a smoke alarm. Sometimes, the smoke (inflammation) isn't just from a burnt toast; it's from a fire that's already spreading. By measuring the "smoke" in the blood (using simple blood tests) and looking closely at the gang's hideout under a microscope, doctors might be able to spot a ticking time bomb that the old maps missed. This is the big question: Can we combine these invisible smoke signals with the visible map details to build a better, more accurate warning system for patients?

Enter the REACT score, a new tool created by a team of researchers to solve exactly this puzzle.

The Detective Work: Building a Better Map

The researchers gathered data from 129 patients who had undergone the standard "clean-up" procedure for rectal cancer: a mix of radiation and chemo followed by surgery to remove the tumor. They wanted to find out which factors were the real culprits behind the cancer coming back (recurrence).

They didn't just look at the tumor size; they looked at the patient's entire "city status." They checked the blood for inflammatory markers. Imagine these as the city's emergency response teams.

• NLR (Neutrophil-to-Lymphocyte Ratio): This compares the number of "first responders" (neutrophils) to the "special forces" (lymphocytes). A high ratio suggests the city is in a panic, but the special forces are outnumbered.
• SII (Systemic Immune-Inflammation Index): This is a more complex score that mixes the platelets (the city's repair crew), neutrophils, and lymphocytes to see how chaotic the whole system is.

They also looked at the tumor itself for specific "bad behavior" signs, like ENE (Extra-nodal Extension). If the cancer gang has broken out of its designated prison (the lymph node) and is running wild in the surrounding tissue, that's a huge red flag. They also checked the CEA level (a protein marker in the blood) and how deep the tumor had dug (pT stage).

The Big Reveal: The REACT Score

After crunching the numbers, the team found that the old maps weren't enough. They discovered five specific "danger signs" that, when combined, could predict a return of the cancer with surprising accuracy. They built a scoring system called REACT, where the letters stand for the key ingredients: Rectal cancer, ENE, Advanced T stage, CEA, and tumor inflammation markers (like NLR and SII).

Here is how the score works, like a traffic light system for risk:

• The Low-Risk Group (0–2 points): These patients had calm blood markers and less aggressive tumors. The result? Only 7.9% of them saw the cancer come back. They are the "green light" group.
• The Intermediate-Risk Group (3–5 points): These patients had some warning signs. About 32.1% of them experienced a recurrence. This is the "yellow light" group.
• The High-Risk Group (6–9 points): These patients had a perfect storm of bad signs: high inflammation, deep tumor invasion, and cancer escaping the lymph nodes. The result was stark: 100% of the patients in this group saw their cancer return during the study's follow-up period. This is the "red light" group.

The researchers tested their new score against a standard statistical method (called an AUC of 0.812), which suggests it is a very strong predictor, much better than guessing.

What the Score Says (and Doesn't Say)

The study suggests that the REACT score is a powerful, low-cost way to sort patients into these three groups after the surgery is complete and the tumor has been analyzed. It combines the "smoke" from preoperative blood tests with the "footprints" left by the tumor in the pathology report (specifically the depth of invasion and whether it escaped the lymph nodes).

However, the authors are careful not to overhype it. They explicitly state that this score does not depend on the type of surgery (open vs. laparoscopic), how much blood was lost during the operation, or whether the patient had a temporary stoma. Those factors, while important for recovery, didn't change the odds of the cancer coming back in their data.

The paper also rules out age as a major factor. Whether a patient was 21 or 85 didn't seem to change their risk of recurrence if the other factors were the same. The real drivers were the biology of the tumor and the body's inflammatory response.

The Bottom Line

The REACT score is a new, simple calculator that uses blood tests and the final pathology report to tell doctors who is likely to need extra vigilance. It suggests that for the high-risk group, the cancer returned in every single case observed in this specific study, meaning these patients might need different, more aggressive follow-up plans. For the low-risk group, it offers hope that they might be in the clear.

The researchers admit this is a "single-city" study (done at one hospital), so the score needs to be tested in other cities to make sure it works everywhere. But for now, it offers a fresh, vivid way to look at rectal cancer: not just as a lump of tissue, but as a battle between a tumor and the body's own defenses, where the smoke signals in the blood tell the true story of the war.